The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition
Article Information
vol. 69 no. 5 882-892
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 9, 2019
- Accepted January 27, 2020
- Published in print April 20, 2020.
- Published online ahead of print January 31, 2020.
Article Versions
- Previous version (January 31, 2020 - 08:48).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2020 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
Author Information
- Megan E. Capozzi1,
- Reilly W. Coch1,2,
- Jepchumba Koech1,
- Inna I. Astapova1,2,
- Jacob B. Wait1,
- Sara E. Encisco1,
- Jonathan D. Douros1,
- Kimberly El1,
- Brian Finan3,
- Kyle W. Sloop4,
- Mark A. Herman1,2,5,
- David A. D’Alessio1,2 and
- Jonathan E. Campbell1,2,5⇑
- 1Duke Molecular Physiology Institute, Duke University, Durham, NC
- 2Division of Endocrinology, Department of Medicine, Duke University, Durham, NC
- 3Novo Nordisk Research Center, Indianapolis, IN
- 4Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
- 5Department of Pharmacology and Cancer Biology, Duke University, Durham, NC
- Corresponding author: Jonathan E. Campbell, jonathan.campbell{at}duke.edu